Language
English
Publication Date
2-1-2024
Journal
Journal of Antimicrobial Chemotherapy
DOI
10.1093/jac/dkad390
PMID
38153245
Abstract
Background: Islatravir is a new antiretroviral drug that inhibits the reverse transcriptase (RT) of HIV-1 through multiple mechanisms. It is proposed to be used in combination with doravirine, a new NNRTI. M184V/I mutations have been shown to reduce the in vitro antiviral activity of islatravir, but their effect when pre-selected during ART has not been investigated.
Methods: HIV-1 rt sequences were obtained from four individuals of the Garrahan HIV cohort prior to, or during virological failure to ART. HIV-1 infectious molecular clones were constructed on an NL4-3 backbone, and infectious viruses were produced by transfection of 293T cells. Fold-changes in IC50 were calculated for each mutant versus the NL4-3 WT. HIV-1 phenotypic drug resistance was tested in vitro against NRTIs and NNRTIs.
Results: In all the cases, M184I/V, either alone or in the presence of other mutations, was associated with reduced susceptibility to islatravir, abacavir and lamivudine. Viruses carrying M184V/I showed variable levels of resistance to islatravir (4.8 to 33.8-fold). The greatest reduction in susceptibility was observed for viruses carrying the mutations M184V + V106I (33.8-fold resistance) or M184V + I142V (25.2-fold resistance). For NNRTIs, the presence of V106I alone did not affect susceptibility to doravirine or etravirine, but showed a modest reduction in susceptibility to efavirenz (6-fold). Susceptibility to doravirine was slightly reduced only for one of the mutants carrying V106I in combination with Y181C and M184V.
Conclusions: Mutations and polymorphisms selected in vivo together with M184V/I depend on the viral genetic context and on ART history, and could affect the efficacy of islatravir once available for use in the clinic.
Keywords
Humans, Anti-HIV Agents, HIV-1, HIV Infections, Lamivudine, Mutation, HIV Reverse Transcriptase, Drug Resistance, Viral, Reverse Transcriptase Inhibitors, Deoxyadenosines
Published Open-Access
yes
Recommended Citation
Aulicino, Paula C; Sharma, Suman; Truong, Khanghy; et al., "Variable Antiviral Activity of Islatravir Against M184I/V Mutant HIV-1 Selected During Antiretroviral Therapy" (2024). Faculty, Staff and Students Publications. 8829.
https://digitalcommons.library.tmc.edu/baylor_docs/8829